172 related articles for article (PubMed ID: 17161613)
1. Beneficial effect of interferon-beta treatment in patients with multiple sclerosis is associated with transient increase in serum IL-6 level in response to interferon-beta injection.
Nakatsuji Y; Nakano M; Moriya M; Kishigami H; Tatsumi C; Tada S; Sadahiro S; Naka T; Mitani K; Funauchi M; Azuma T; Watanabe S; Kinoshita M; Kajiyama K; Yuasa Y; Kaido M; Takahashi MP; Naba I; Hazama T; Sakoda S;
Cytokine; 2006 Oct; 36(1-2):69-74. PubMed ID: 17161613
[TBL] [Abstract][Full Text] [Related]
2. Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha.
Nicoletti F; Di Marco R; Patti F; Zaccone P; L'Episcopo MR; Reggio E; Xiang M; Nicoletti A; Reggio A
Cytokine; 2000 Jun; 12(6):682-7. PubMed ID: 10843745
[TBL] [Abstract][Full Text] [Related]
3. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B
Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta1a.
Perini P; Tiberio M; Sivieri S; Facchinetti A; Biasi G; Gallo P
Eur Cytokine Netw; 2000 Mar; 11(1):81-6. PubMed ID: 10705303
[TBL] [Abstract][Full Text] [Related]
5. Time of interferon-beta 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients.
Kümpfel T; Schwan M; Pollmächer T; Yassouridis A; Uhr M; Trenkwalder C; Weber F
Mult Scler; 2007 Nov; 13(9):1138-45. PubMed ID: 17967841
[TBL] [Abstract][Full Text] [Related]
6. Long-term favorable response to interferon beta-1b is linked to cytokine deviation toward the Th2 and Tc2 sides in Japanese patients with multiple sclerosis.
Mei FJ; Osoegawa M; Ochi H; Minohara M; Nan S; Murai H; Ishizu T; Taniwaki T; Kira J
J Neurol Sci; 2006 Jul; 246(1-2):71-7. PubMed ID: 16581087
[TBL] [Abstract][Full Text] [Related]
7. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
8. Clinical parameters to predict response to interferon in relapsing multiple sclerosis.
Fromont A; Debouverie M; Le Teuff G; Quantin C; Binquet C; Moreau T
Neuroepidemiology; 2008; 31(3):150-6. PubMed ID: 18716412
[TBL] [Abstract][Full Text] [Related]
9. Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis.
Wiesemann E; Deb M; Hemmer B; Radeke HH; Windhagen A
Clin Immunol; 2008 Sep; 128(3):306-13. PubMed ID: 18539537
[TBL] [Abstract][Full Text] [Related]
10. The interleukin-10 levels as a potential indicator of positive response to interferon beta treatment of multiple sclerosis patients.
Bartosik-Psujek H; Stelmasiak Z
Clin Neurol Neurosurg; 2006 Oct; 108(7):644-7. PubMed ID: 16343740
[TBL] [Abstract][Full Text] [Related]
11. Expression of TNF-alpha mRNA by peripheral blood mononuclear cells of multiple sclerosis patients treated with IFN-beta 1A.
Sarchielli P; Critelli A; Greco L; Sokola E; Floridi A; Gallai V
Cytokine; 2001 Jun; 14(5):294-8. PubMed ID: 11444910
[TBL] [Abstract][Full Text] [Related]
12. The effect of beta-interferon therapy on myelin basic protein-elicited CD4+ T cell proliferation and cytokine production in multiple sclerosis.
Hedegaard CJ; Krakauer M; Bendtzen K; Sørensen PS; Sellebjerg F; Nielsen CH
Clin Immunol; 2008 Oct; 129(1):80-9. PubMed ID: 18653385
[TBL] [Abstract][Full Text] [Related]
13. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.
Weinstock-Guttman B; Bhasi K; Badgett D; Tamaño-Blanco M; Minhas M; Feichter J; Patrick K; Munschauer F; Bakshi R; Ramanathan M
J Neuroimmunol; 2008 Dec; 205(1-2):113-25. PubMed ID: 18950872
[TBL] [Abstract][Full Text] [Related]
14. Changes of percentages in immune cells phenotypes and cytokines production during two-year IFN-beta-1a treatment in multiple sclerosis patients.
Mirowska D; Skierski J; Paź A; Koronkiewicz M; Zaborski J; Kruszewska J; Członkowski A; Członkowska A
J Neurol; 2003 Oct; 250(10):1229-36. PubMed ID: 14586608
[TBL] [Abstract][Full Text] [Related]
15. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity.
Krumbholz M; Faber H; Steinmeyer F; Hoffmann LA; Kümpfel T; Pellkofer H; Derfuss T; Ionescu C; Starck M; Hafner C; Hohlfeld R; Meinl E
Brain; 2008 Jun; 131(Pt 6):1455-63. PubMed ID: 18474519
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
[TBL] [Abstract][Full Text] [Related]
17. Predictive markers for response to interferon therapy in patients with multiple sclerosis.
Malucchi S; Gilli F; Caldano M; Marnetto F; Valentino P; Granieri L; Sala A; Capobianco M; Bertolotto A
Neurology; 2008 Mar; 70(13 Pt 2):1119-27. PubMed ID: 18272865
[TBL] [Abstract][Full Text] [Related]
18. Pro-inflammatory cytokine and chemokine mRNA blood level in multiple sclerosis is related to treatment response and interferon-beta dose.
Cucci A; Barbero P; Clerico M; Ferrero B; Versino E; Contessa G; Demercanti S; Viglietta E; Di Liberto A; Vai AG; Durelli L
J Neuroimmunol; 2010 Sep; 226(1-2):150-7. PubMed ID: 20573405
[TBL] [Abstract][Full Text] [Related]
19. Expression of Th1 and Th17 cytokines and transcription factors in multiple sclerosis patients: does baseline T-bet mRNA predict the response to interferon-beta treatment?
Drulovic J; Savic E; Pekmezovic T; Mesaros S; Stojsavljevic N; Dujmovic-Basuroski I; Kostic J; Vasic V; Mostarica Stojkovic M; Popadic D
J Neuroimmunol; 2009 Oct; 215(1-2):90-5. PubMed ID: 19695714
[TBL] [Abstract][Full Text] [Related]
20. Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response.
Carmona O; Casado V; Moral E; Alonso-Magdalena L; Martínez-Yélamos A; Martínez-Yélamos S; Martín-Ozaeta G; Arbizu T
Eur Neurol; 2008; 60(6):279-84. PubMed ID: 18824855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]